Companies › GILD
GILEAD SCIENCES INC (GILD)
Institutional ownership, SEC filings and insider activity
Sector: Healthcare & Pharma · SEC CIK 0000882095 · EDGAR filings · Updated 2026-07-16
GILEAD SCIENCES INC (GILD) has reported institutional ownership of 85.2%, with 2,292 institutional managers holding positions valued at $147.3B per the latest 13F reporting period. The company has 10 bond series in the registry.
Latest updates
- 2026-07-16 — Insider transaction reported (Form 4)
- 2026-07-16 — Insider transaction reported (Form 4)
- 2026-07-15 — Notice of proposed sale filed (Form 144)
- 2026-07-15 — Notice of proposed sale filed (Form 144)
- 2026-07-02 — Insider transaction reported (Form 4)
- 2026-06-16 — Insider transaction reported (Form 4)
- 2026-06-16 — Insider transaction reported (Form 4)
- 2026-06-15 — Notice of proposed sale filed (Form 144)
Institutional ownership overview
According to SEC 13F filings tracked by Sightfile, GILEAD SCIENCES INC has 2,292 institutional holders and institutional ownership of 85.2%.
| # | Institution | Reported value | % of tracked total |
|---|---|---|---|
| 1 | BlackRock, Inc. | $16.6B | 11.3% |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | $11.2B | 7.6% |
| 3 | FMR LLC | $10.0B | 6.8% |
| 4 | STATE STREET CORP | $8.34B | 5.7% |
| 5 | Capital World Investors | $5.75B | 3.9% |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | $4.90B | 3.3% |
| 7 | JPMORGAN CHASE & CO | $4.63B | 3.1% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | $4.14B | 2.8% |
| 9 | Capital Research Global Investors | $3.78B | 2.6% |
| 10 | PRICE T ROWE ASSOCIATES INC /MD/ | $3.66B | 2.5% |
Full holder history and quarter-over-quarter changes are available inside the app.
Insider activity
Insiders reported 144 transactions (0 buys, 63 sells) across 15 reporting insiders, with a net reported value of −$76.2M.
Quarterly net insider value, as reported in Form 4 filings.
Debt profile
10 active bond series in the registry, coupons ranging 4.25%–5.60%, maturities through 2064, built from the company's own prospectus filings.
Debt maturity schedule
Principal coming due by year for GILEAD SCIENCES INC, from the company's own SEC prospectus filings (424B) tracked by Sightfile.
| Year | Bond series maturing | Known principal due |
|---|---|---|
| 2027 | 2 | — |
| 2028 | 1 | — |
| 2029 | 2 | — |
| 2030 | 1 | — |
| 2031 | 1 | — |
| 2033 | 1 | $1.00B |
| 2034 | 1 | — |
| 2035 | 2 | — |
| 2036 | 1 | — |
| 2040 | 1 | — |
| 2041 | 1 | — |
| 2044 | 1 | — |
Coupons, seniority and prospectus links for each series are available inside the app.
Related companies
MERCK & CO. INC. (MRK) · AMGEN INC (AMGN) · ASTRAZENECA PLC (AZN) · ABBOTT LABS (ABT) · INTUITIVE SURGICAL INC (ISRG) · PFIZER INC (PFE)
See full history, cross-references and alerts on SightfileData sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-16.